Our Science – Lee Website
Jung-Min Lee, M.D.
Dr. Lee is a participating member in the Gynecologic Oncology Group, American Association for Cancer Research, American Society for Clinical Oncology, and the Breast and Gynecologic Malignancies Faculty of the CCR. She was awarded the 2011 Jane C. Wright M.D. Young Investigator Award from the American Society of Clinical Oncology and the 2012 New York Ovarian Cancer Research Award from the Foundation for Women's Cancers.
Dr. Lee's research interests include the early clinical drug development and translational studies of targeted agents in triple negative breast cancer (TNBC) and ovarian cancer, as these diseases share the similar molecular abnormalities, such as TP53 and Rb mutations. Her translational and clinical research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and apoptotic pathways in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents. Dr. Lee's ASCO Young Investigator Award project is to test hypothesis of underlying sequence specificity of DNA damage by a PARP inhibitor and carboplatin, both at the preclinical and clinical levels. In addition, her New York Ovarian Cancer Research Award project is to develop a flow cytometric method to examine potential biomarkers of response to PARP inhibitor therapy in high-grade ovarian cancer. Dr. Lee's group is also interested in pursuing other potential biomarkers of response to targeted agents for cell cycle, apoptotic pathways, and targeted pathways pertinent to TNBC and high-grade serous ovarian cancer. She looks forward to advancing the preclinical biomarker and activity data into new clinical studies for women's cancers.
This page was last updated on 2/27/2013.